vorinostat,pembrolizumab
merck
['lcsm,(-blcsm)', 'vorinostat', 'thank you', 'pembro', 'nsclc', 'sclc']
thank you to dr andreas saltos of for expanding on final results from a phase 2 trial of first-line pembrolizumab and vorinostat in patients with metastatic nsclc. visit us at to hear more! #asco23 #asco2023 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.